HIV market to surpass $32 billion across 7MM in 2033

9 May 2025

The human immunodeficiency virus (HIV) market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK and Japan) is forecast to grow at a compound annual growth rate (CAGR) of 1.9% from $26.5 billion in 2023 to $32.1 billion in 2033, pharma analytics company GlobalData forecasts.

GlobalData’s report, “Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast,” reveals that market growth will primarily be driven by the increased uptake of long-acting injectable therapies, as well as the anticipated launch of novel single tablet regimens (STRs).

Anaelle Tannen, GlobalData’s infectious disease analyst, commented: “The pipeline analysis indicates a shift away from 3-drug STRs and towards 2-drug STRs. These are hoped to have reduced toxicities and side effects as a result.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical